Dr.PathRoch said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.
Dr.NutriCornell said:The mechanism is more central than most summaries suggest.
This is exactly what I could not find anywhere else. Adding it to my notes with a link back to this thread.
Dr.PathRoch said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
Worth saying that the confident version of this is more useful to the person writing it than to the person reading it.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThe figures, for anyone assembling their own picture. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.
Moderator note: the sourcing question belongs in the vendor section and has been split out. Carry on.